Author Affiliations: Unità Operativa di Medicina Generale, Saronno Hospital (Drs Monti and Saccardo); Istituto di Medicina Interna II e Ematologia, S Gerardo Hospital, Monza (Dr Pioltelli); Unità Operativa di Medicina Generale, Novara Hospital (Dr Campanini); Istituto di Clinica Medica, University of Ancona (Drs Candela and Gabrielli); Unità Operativa Medicina Generale, S Croce Hospital, Cuneo (Dr Cavallero); Istituto di Reumatologia, University of Udine (Dr De Vita); Istituto di Patologia Medica e Reumatologia, University of Pisa (Dr Ferri); Unità Operativa di Medicina Generale, Pordenone Hospital (Dr Mazzaro); Istituto di Clinica Medica e Reumatologia, University of Naples (Dr Migliaresi); Istituto di Medicina Interna, University of Padua (Dr Ossi); Istituto di Medicina Interna, S Paolo Hospital, University of Milan (Drs Pietrogrande and Invernizzi); and Istituto di Malattie Infettive e Tropicali, L Sacco Hospital, University of Milan (Dr Galli), Italy.
Some patients with cryoglobulinemic syndrome (CS) develop frank non-Hodgkin lymphoma (NHL), but the incidence and timing of this event are still poorly defined.
A retrospective multicenter study was performed of hepatitis C virus–positive patients with CS observed in 11 Italian centers belonging to the Italian Group for the Study of Cryoglobulinemia.
The inclusion criteria were satisfied by 1255 patients. During a cumulative follow-up of 8928 patient-years, 59 cases of NHL were diagnosed, for an estimated rate of 660.8 new cases per 100 000 patient-years with 224.1 new cases of aggressive NHL subtypes per 100 000 patient-years. More than 90% of the patients developing NHLs had type II cryoglobulins. The NHLs were classified as nonaggressive in 31 cases (53%), aggressive in 20 (34%), and mucosa-associated lymphoid tissue lymphomas in 6 (10%); 2 cases were unclassifiable. The median time from the diagnosis of CS to the clinical onset of NHL was 6.26 years (range, 0.81-24 years). The clinical course and response to chemotherapy in the patients with CS who had NHL were similar to those usually described in patients with NHL without CS; the course of the CS only marginally benefited from chemotherapy.
The overall risk of NHL in patients with CS is about 35 times higher than in the general population (12 times higher if nonaggressive lymphomas are excluded). The presence of CS did not significantly affect the treatment of newly diagnosed lymphomas.
Mixed cryoglobulinemias are immunocomplex-related disorders that lead to cutaneous and systemic vasculitis, glomerulonephritis, and peripheral neuropathy.1- 4 The cold-precipitating immune complexes are formed by immunoglobulins and monoclonal or polyclonal IgM rheumatoid factor and respectively classified as type II and type III mixed cryoglobulinemias.5
Both cryoglobulinemic syndrome (CS) and its progression to overt lymphomas1- 3 were reported many years before the discovery of the association between CS and hepatitis C virus (HCV) infection, and it has more recently been suggested that there is a relationship between HCV infection and an increased risk of developing non-Hodgkin lymphoma (NHL) regardless of the presence of CS,6,7 although this has not been confirmed in larger epidemiologic studies.8
Studies of relatively small case files recruited in a single center may overestimate the incidence of NHL in patients with HCV-associated CS and do not permit comparisons with the general population. Furthermore, the pathological features of the lymphoproliferation itself is puzzling because a lymphoid monoclonal infiltrate without progression to overt malignancy is usually found in the marrow and liver biopsy specimens of patients with CS,9,10 and the time interval between the diagnosis of CS and the clinical evidence of lymphoma is still poorly defined. Finally, the role of interferon in reducing the incidence of lymphoma needs thorough investigation, as does the effect of chemotherapy on cryoglobulin production and CS-related symptoms.
This study was designed to answer some of these questions by retrospectively assessing the cumulative incidence and characteristics of NHL in a large series of patients with CS observed in 11 centers belonging to the Italian Group for the Study of Cryoglobulinemia.
This retrospective multicenter study included all of the patients registered at the 11 centers situated in 7 Italian regions (3 in Lombardy, 2 in Piedmont, 2 in Friuli, and 1 each in Tuscany, the Veneto, Marche, and Campania) for whom stored serum samples were available in January 1993 for the assessment of HCV status, or who could be directly screened for the virus. The centers were asked to report the date on which all of the patients included in the cohort were diagnosed as having CS, and any incident NHL cases occurring before the end of December 2002, with the date of diagnosis, histologic findings, and clinical outcome. The NHLs diagnosed before or within 6 months after the onset of CS were not considered.
Hepatitis C virus infection was diagnosed by means of HCV RNA determinations, and only HCV RNA–positive patients were included in the study. Stored serum samples were used to test HCV RNA in the patients with CS diagnosed before 1993, who contributed to the analysis with the entire time of observation from CS diagnosis.
The standardized diagnosis of CS required the presence of serum cryoglobulins (cryocrit concentration, >1%) for more than 6 months; at least 2 of purpura, weakness, and arthralgia; and C4 levels less than 8 mg/dL and/or positive serum rheumatoid factor. The serum samples were collected; the cryoglobulins quantified, isolated, and characterized; and the serum C4 levels and rheumatoid factor activity determined as previously described.3
As a general policy adopted by the Italian Group for the Study of Cryoglobulinemia since 1993, the patients underwent bone marrow biopsy, abdominal sonography, and standard chest radiography at the time of the diagnosis of CS. The abdominal scans and chest radiograms were repeated every other year during the follow-up, whereas the marrow was reexamined only in the case of abnormal peripheral-blood findings or as part of the staging procedure for a newly diagnosed lymphoma.
A percutaneous liver biopsy was recommended in all of the patients with abnormal alanine aminotransferase levels. The diagnosis of NHL was made on the basis of evidence of nodal or extranodal lymphoproliferative disease with pathological features that were compatible with the criteria of the Armed Forces Institute of Pathology–World Health Organization guidelines.11 When bone marrow monoclonal lymphoproliferation was the only reported pathological finding, a diagnosis of NHL was arbitrarily accepted in the presence of bone marrow substitution of 30% or greater and/or the onset or worsening of peripheral-blood cytopenia (hemoglobin level, <10 g/dL; platelet count, <100 × 103/μL; neutrophil count, <103/μL).
All of the NHL diagnoses were centrally reviewed. The working formulation was used to classify the NHLs, with an additional subset for mucosa-associated lymphomas. To reduce data dispersion, they were further defined as nonaggressive (including lymphocytic and small-cell follicular lymphomas) or aggressive (including large-cell follicular, mixed diffuse, and large-cell centroblastic; immunoblastic; and lymphoblastic lymphomas); these 2 categories roughly correspond to the low and intermediate-high grades of the working formulation.
An improvement in CS was defined as the complete disappearance of, or substantial reduction in, purpuric manifestations, weakness, and arthralgias, accompanied by an increase in C4 levels and/or a decrease in cryocrit levels and serum rheumatoid factor titers. An improvement in liver disease was defined as alanine aminotransferase levels of less than the upper reference value or their halving at least 3 times during 6 months. Complete lymphoma remission was defined as the total disappearance of the lymphomatous mass, and partial remission as a 75% reduction.
The statistical analyses were made with BMDP software (BMDP Statistical Software Inc, Los Angeles, Calif). The distributions of the nonparametric variables were studied with contingency tables and compared with Pearson χ2 test; the continuous variables were compared with Gosset unpaired t test. The time-dependent risks were assessed by means of the life-table method and compared by Mantel test; cumulative hazard ratios were computed from the negative natural logarithm of survival function.
When applicable, multiple comparisons were corrected by the Bonferroni method.
A total of 1255 HCV-positive patients with CS were included in the study. During the total follow-up period of 8928 person-years, 59 patients fulfilled the criteria for an NHL diagnosis, with an estimated incidence of 660.8 new cases per 100 000 patient-years; there were 20 aggressive NHLs, an incidence of 224.1 new cases per 100 000 patient-years.
The cumulative incidence of NHL varied from 2.1% to 11.4% in the different centers. Fifty (93%) of the 54 patients for whom the results of immunochemical cryoprecipitate testing were available had type II cryoglobulins. The overall median time between the diagnoses of CS and NHL was 6.26 years (range, 0.81-24 years); in the aggressive lymphoma subset, it was 3.5 years (range, 0.5-23 years). Forty-three patients showed histologic evidence of chronic active hepatitis or cirrhosis at the time of NHL diagnosis. The NHLs were classified as nonaggressive in 31 cases, aggressive in 20, and mucosa-associated lymphoid tissue (MALT) lymphomas in 6; 2 cases were unclassifiable (Table 1). Among nonaggressive lymphomas, 16 had bone-marrow infiltration as the only reported pathological finding; considering the 20 aggressive and 15 nonaggressive NHL cases not restricted to the bone marrow, the overall incidence of overt lymphomas was 329.0 per 100 000 patient-years.
After the diagnosis of NHL, the patients were followed up for a median of 5 years (range, 1-24 years); their actuarial median survival estimated by the life-table method was 10.61 years. The 2 patients with histologically unclassifiable cases were still alive after 2 and 16 years of follow-up; 24 of the other patients died (8 of NHL-related causes, 3 of liver disease, and 13 of causes unrelated to CS or NHL).
Twenty-five patients received standard courses of alfa-2b interferon treatment before developing NHL; this treatment did not influence the time between the diagnoses of CS and NHL, which was 4.8 years for the untreated patients and 4.0 years for the treated patients (P = .38).
One patient achieved complete remission after spleen irradiation alone and was still in remission after 14 years; 39 received standard chemotherapy (CHOP [cyclophosphamide, doxorubicin, vincristine sulfate, and prednisone], MACOP [methotrexate, doxorubicin, cyclophosphamide, vincristine, and prednisone], CVP [cyclophosphamide, vincristine, and prednisone]).
Chemotherapy seemed to improve the survival of the patients with nonaggressive lymphomas, as the treated patients survived longer than those who were untreated (P = .04). All but 1 of the patients with an aggressive lymphoma were treated. The effect of treatment was not influenced by age at lymphoma diagnosis, the presence of liver cirrhosis, or cryocrit levels.
Twenty of the 39 patients receiving chemotherapy died: the causes of death were progressive lymphoma in 6 cases, cardiovascular complications in 3, liver failure in 3, esophageal bleeding in 1, pneumonia in 1, lung cancer in 1, cerebral hemorrhage in 1, and undetermined in 4.
One of the 20 patients who did not receive chemotherapy was a 79-year-old woman with a poor performance status affected by a large-cell centroblastic lymphoma with a high disease burden (nodes, bone marrow, liver, and spleen), who died of spleen rupture 6 months after diagnosis. Of the remaining 19 patients, 3 had gastric MALT lymphomas, 1 had a lymphocytic lymphoma with single-node involvement and died of sepsis, and 15 had exclusively bone marrow involvement (11 lymphocytic, 3 small-cell follicular, and 1 unclassifiable lymphoma). Three of these patients died during the observation period (1 because of NHL progression).
The CS worsened after chemotherapy in 16 patients who experienced more frequent episodes of purpura. On the contrary, chemotherapy was associated with an improvement in CS-related symptoms in 19 patients, although serum cryoglobulins disappeared in only 6 cases. Liver disease progressed in 17 patients, 5 of whom died of liver failure; 7 patients showed a lasting improvement in liver function indexes without any histologic evidence of progressive liver disease (Table 2).
Our results confirm that the overall incidence of NHL, as well as the incidence of aggressive histotypes, is higher in patients with HCV-related CS than in the general population, and there is an excess of MALT and low-grade lymphoma in these patients. They also suggest that interferon treatment does not have a major influence on the risk of developing NHL.
The incidence of NHL reported by the participating centers varied considerably and was higher in the centers that contributed fewer patients. The overall cumulative incidence was 4.7% and that of aggressive histotypes was 1.6%, which is lower than the 7% to 11% reported in other published Italian series.4,9,12 This difference may be explained by the smaller size of these studies and, perhaps, their less restrictive inclusion criteria. Nevertheless, in comparison with the annual incidence of 18.6 new cases of NHL per 100 000 inhabitants13 reported by the Registro Tumori della Lombardia–provincia di Varese, the incidence of NHL in patients with CS is more than 35.5 times the expected figure and remains 12 times higher even if only the aggressive histotypes are considered.
Only 9% of our cases had high-grade large-cell or lymphoblastic lymphomas, which is similar to the 7% reported by La Civita et al12 but clearly different from findings in the general population, in which 60% of NHLs are “aggressive” (ie, large-cell follicular, mixed diffuse, and large-cell centroblastic, immunoblastic, and lymphoblastic lymphomas).14
Our data are also markedly different from those of studies investigating the prevalence of HCV infection in patients with lymphomas: Pioltelli et al8 reported that 66.7% of 48 HCV-positive NHLs observed in Lombardy, Italy, were “aggressive”; De Vita et al15 found mainly high-grade large B-cell lymphomas in HCV-infected patients; and Ferri et al16 reported that two thirds of 34 B-cell NHLs in HCV-infected patients were intermediate- or high-grade lymphomas. Findings similar to our own have been reported only when the clinical picture corresponded to that of CS (with kidney or liver involvement and circulating cryoglobulins), as in 17 of 35 HCV-positive patients with prevalently low-grade lymphoproliferation (immunocytomas) described by Silvestri et al.17
We included “low-grade” lymphomas with exclusively bone marrow involvement in an attempt to address the question of how to interpret them. In some respects, our findings support the view that they should be considered examples of CS-associated monoclonal lymphoproliferation (probably the pathological counterpart of serologic findings) rather than true lymphomas, although the possibility that they represent a transitional form leading to overt lymphoma cannot be excluded.
MALT lymphomas were more frequent in our study than in the HCV-positive NHL series of Pioltelli et al8 (10% vs 6.5% of cases). Further investigations are needed to verify whether this unusual prevalence in areas in which the incidence of MALT is otherwise about 7% of all B-cell lymphomas is causally attributable to the virus.
Most of the patients with CS who developed NHL in our study and previously published series had type II cryoglobulins. This is a third peculiarity of this type of cryoglobulinemia, which is more frequently associated with renal impairment and less frequently with severe liver disease than type III.18,19
Interferon therapy did not seem to influence the risk of lymphoma or the time of its development. Sansonno et al20 observed the occurrence of B-cell NHLs in cryoglobulinemic patients whose HCV RNA cleared after interferon therapy, thus suggesting that factors other than HCV are also involved in lymphomagenesis. However, none of our patients showed a sustained viral response to interferon therapy, and none of the incident NHLs was observed in patients in whom HCV RNA had become stably negative.
The response to chemotherapy of the 39 treated patients was comparable with that observed in HCV- and CS-negative patients with NHL: 11 patients (28%) were still alive after 5 years. Chemotherapy did not significantly influence the clinical course of CS, but CS seems to have a favorable clinical trend in patients who respond well to chemotherapy.
The transition from early bone marrow and liver B-lymphocyte infiltrates to overt lymphoproliferation, which was first reported in patients with CS by Monteverde et al,9,10 is still unexplained. Lymphoid aggregates in the liver are more common in patients with type II than in those with type III CS or noncryoglobulinemic chronic hepatitis and have many of the features usually considered to be markers of malignant lymphoid proliferation: Bcl-2 overexpression, monotypical IgM κ restriction of cryoglobulin production,21,22 and a high rate of monoclonal IgM rearrangements. Many authors have attributed these characteristics to HCV infection and considered them markers of oligoclonal nonneoplastic B-cell expansion; however, they are so frequent in low-grade lymphomas (regardless of viral status) that they are usually considered to be neoplastic markers and are currently used as indicators of residual disease. In molecular terms, the lymphoid infiltrates associated with CS are similar to those of overt low-grade lymphomas, the only differences being their slower growth and clinical features. It therefore remains to be established whether HCV infection not only triggers the events leading to CS but is also a first step toward lymphomagenesis.23
Dammacco et al24 identified 2 types of B-cell NHLs associated with HCV infection: the NHLs arising in cryoglobulinemic patients, which usually have a low-malignancy phenotype but may occasionally evolve into a high-malignancy phenotype; and the NHLs not associated with cryoglobulinemia, which usually do not involve the bone marrow and are frequently highly malignant from the start.
Our finding that the vast majority of patients with CS do not develop an overt malignancy during a long follow-up period suggests that a number of individual and environmental factors may be involved.
The major limitations of our study include its retrospective design and the difficulty of distinguishing CS with bone marrow infiltrates (a common finding in type II CS) from CS with bone marrow–infiltrating NHLs without any other localization. Furthermore, systemic symptoms may reduce the sensitivity and specificity of our observations. Nevertheless, the large number of patients and our efforts to standardize the data collection criteria make us confident about the reliability of our findings.
In conclusion, patients with CS show an unusually high incidence of high-grade and low-grade NHLs, as well as MALT lymphomas, in comparison with the general population. Hepatitis C virus remains highly suspected as the cause of these phenomena, but its role remains to be assessed in more detailed longitudinal studies. Despite the fact that their long-lasting chronic disease compromises the function of a number of organs, patients with CS seem to tolerate chemotherapy for NHL well.
Correspondence: Massimo Galli, MD, Institute of Infectious Diseases and Tropical Medicine, University of Milan, L Sacco Hospital, Via G B Grassi 74, 20157 Milano, Italy (email@example.com).
Accepted for Publication: August 23, 2004.
Financial Disclosure: None.
Thank you for submitting a comment on this article. It will be reviewed by JAMA Internal Medicine editors. You will be notified when your comment has been published. Comments should not exceed 500 words of text and 10 references.
Do not submit personal medical questions or information that could identify a specific patient, questions about a particular case, or general inquiries to an author. Only content that has not been published, posted, or submitted elsewhere should be submitted. By submitting this Comment, you and any coauthors transfer copyright to the journal if your Comment is posted.
* = Required Field
Disclosure of Any Conflicts of Interest*
Indicate all relevant conflicts of interest of each author below, including all relevant financial interests, activities, and relationships within the past 3 years including, but not limited to, employment, affiliation, grants or funding, consultancies, honoraria or payment, speakers’ bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued. If all authors have none, check "No potential conflicts or relevant financial interests" in the box below. Please also indicate any funding received in support of this work. The information will be posted with your response.
Some tools below are only available to our subscribers or users with an online account.
Download citation file:
Web of Science® Times Cited: 60
Customize your page view by dragging & repositioning the boxes below.
Enter your username and email address. We'll send you a link to reset your password.
Enter your username and email address. We'll send instructions on how to reset your password to the email address we have on record.
Athens and Shibboleth are access management services that provide single sign-on to protected resources. They replace the multiple user names and passwords necessary to access subscription-based content with a single user name and password that can be entered once per session. It operates independently of a user's location or IP address. If your institution uses Athens or Shibboleth authentication, please contact your site administrator to receive your user name and password.